ORIG3N, a Boston-based biotechnology company, is collaborating with Laboratory Corporation of America Holdings (LabCorp), a healthcare diagnostics company. LabCorp has invested in ORIG3N and will provide storage for LifeCapsule, ORIG3N’s induced pluripotent stem cell (iPSC) storage, at its biorepository facilities as well as perform genetic testing on the stored cells. LabCorp's experience will help to accelerate the development of LifeCapsule's specimen repository.
LifeCapsule's repository is utilized to generate induced pluripotent stem cells (iPSCs). These cells can be differentiated to every other cell type in the human body, which aids in more accurate disease modeling and drug efficacy testing. The repository will enable access to a large, genetically diverse population of iPSCs for biotechnology and pharmaceutical companies, supporting development of treatments for a variety of diseases. The strategic partnership between ORIG3N and LabCorp will increase the utility of LifeCapsule and establish a well-characterized library of specimens.
"Having access to LabCorp's technical operations, logistics expertise and testing platforms is valuable," said Robin Y. Smith, CEO and co-founder at ORIG3N. "LifeCapsule is rapidly growing into one of the world's largest cell repositories, and we have collected thousands of samples to date."